If you’ve been diagnosed with major depressive disorder or a form of anxiety, your mental health provider may prescribe the ...

As I was taking a psyco-social medical history of a 43-year-old woman, I asked, “What is your problem?” She replied, “I can’t ...

Pristiq (desvenlafaxine) and Effexor (venlafaxine) are SNRIs. Pristiq treats depression, while Effexor treats depression and ...

Ahead, OB/GYNs share a super common and relatable example (plus a few more), along with the risks. Related: The Test You ...

The German company’s drug met all the goals of a late-stage study for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes, caused by breast-cancer treatments.

Medically reviewed by Renita White, MD Perimenopause is the transition period when the female body starts to shift from reproductive age into menopause (when menstrual cycles stop completely). This ...

Purpose: The association of antipsychotic and antidepressant drugs with Q-T interval prolongation is reviewed. Summary: Prolongation of the Q-T interval can be of particular concern to ...

A monk was apprehended for drug use and allegedly deceiving a young boy at a temple in Buriram, following a tip-off from a concerned citizen. The citizen presented video evidence of the monk’s drug ...

Lexapro (escitalopram), Elavil (amitriptyline), and Tofranil (imipramine) are common medications prescribed to treat symptoms of depression. Research reveals that caffeine forms a complex with ...

Hot flashes, a typical sign of menopause, may impact as many as 85% of women. These are defined by a sudden sensation of warmth that sweeps over the whole body, frequently followed by perspiration ...

Disappointing trial results for Novo Nordisk A/S’s experimental obesity shot capped a volatile year for investors in drug developers vying for a piece of pharma’s hottest market.

(Bloomberg) -- Disappointing trial results for Novo Nordisk A/S’s experimental obesity shot capped a volatile year for investors in drug developers ... Despite a not-so-hot year, some investors ...